Literature DB >> 29173524

Fecal Transplant in Inflammatory Bowel Disease.

Alexander S Browne1, Colleen R Kelly2.   

Abstract

Patients with inflammatory bowel disease (IBD) have differences in their gastrointestinal microbiome compared with healthy individuals, although it is unclear whether this is a cause or consequence of chronic inflammation. There is hope that manipulation of the gut microbiome through fecal microbiota transplant (FMT), commonly used to treat patients with Clostridium difficile infection, may also be an effective therapy in IBD. This article reviews the evidence supporting FMT in IBD, including case reports, case series, and randomized controlled trials. The article also focuses on questions of safety and speculates on the future of this therapy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Crohn disease; Dysbiosis; FMT; Fecal transplant; IBD; Ulcerative colitis

Mesh:

Year:  2017        PMID: 29173524     DOI: 10.1016/j.gtc.2017.08.005

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  10 in total

Review 1.  Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease.

Authors:  Jin Ah Cho; Daniel J F Chinnapen
Journal:  J Microbiol       Date:  2018-02-28       Impact factor: 3.422

Review 2.  The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis.

Authors:  Wai Ching Lam; Chen Zhao; Wen Juan Ma; Liang Yao
Journal:  Gastroenterol Res Pract       Date:  2019-04-15       Impact factor: 2.260

Review 3.  Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery.

Authors:  Michael Kriss; Keith Z Hazleton; Nichole M Nusbacher; Casey G Martin; Catherine A Lozupone
Journal:  Curr Opin Microbiol       Date:  2018-07-20       Impact factor: 7.934

Review 4.  Acute Radiation Syndrome and the Microbiome: Impact and Review.

Authors:  Brynn A Hollingsworth; David R Cassatt; Andrea L DiCarlo; Carmen I Rios; Merriline M Satyamitra; Thomas A Winters; Lanyn P Taliaferro
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

5.  Coprophagy in nineteenth-century psychiatry.

Authors:  Alison M Moore
Journal:  Microb Ecol Health Dis       Date:  2018-11-08

Review 6.  Understanding the microbiome: a primer on the role of the microbiome in colorectal neoplasia.

Authors:  Katherine M Watson; Christopher A Gaulke; Vassiliki Liana Tsikitis
Journal:  Ann Gastroenterol       Date:  2020-03-14

Review 7.  Probiotic Gastrointestinal Transit and Colonization After Oral Administration: A Long Journey.

Authors:  Shengyi Han; Yanmeng Lu; Jiaojiao Xie; Yiqiu Fei; Guiwen Zheng; Ziyuan Wang; Jie Liu; Longxian Lv; Zongxin Ling; Björn Berglund; Mingfei Yao; Lanjuan Li
Journal:  Front Cell Infect Microbiol       Date:  2021-03-10       Impact factor: 5.293

8.  A Rapid Screening Method of Candidate Probiotics for Inflammatory Bowel Diseases and the Anti-inflammatory Effect of the Selected Strain Bacillus smithii XY1.

Authors:  Xuedi Huang; Fang Ai; Chen Ji; Pengcheng Tu; Yufang Gao; Yalan Wu; Fujie Yan; Ting Yu
Journal:  Front Microbiol       Date:  2021-12-17       Impact factor: 5.640

9.  Fecal Microbiota Transplantation Ameliorates Active Ulcerative Colitis by Downregulating Pro-inflammatory Cytokines in Mucosa and Serum.

Authors:  Wen-Hui Zhang; Ze-Yu Jin; Zhong-Hua Yang; Jia-Yi Zhang; Xiao-Han Ma; Jing Guan; Bao-Lin Sun; Xi Chen
Journal:  Front Microbiol       Date:  2022-04-04       Impact factor: 6.064

10.  Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis.

Authors:  Marianne R Spalinger; Marlene Schwarzfischer; Larissa Hering; Ali Shawki; Anica Sayoc; Alina Santos; Claudia Gottier; Silvia Lang; Katharina Bäbler; Annelies Geirnaert; Christophe Lacroix; Gabriel E Leventhal; Xuezhi Dai; David Rawlings; Andrew A Chan; Gerhard Rogler; Declan F McCole; Michael Scharl
Journal:  Mucosal Immunol       Date:  2019-09-09       Impact factor: 7.313

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.